26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00463567 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

2059

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive
COPD
Lung Diseases, Obstructive

Interventions

DRUG: Indacaterol
DRUG: Formoterol (12 µg b.i.d.)
DRUG: Tiotropium (18 µg o.d.)
DRUG: Placebo to Indacaterol
DRUG: Placebo to Formoterol

Sponsor

Novartis